SDIP is a private company developing the next generation of bioresorbable bone-implant systems called JAZBI™. In pre-clinical studies, JAZBI™ is superior to other bone implants as it degrades into neutral products. It completely resorbs from bulk and avoids inflammation resulting in excellent re-store and bone re-growth. SDIP`s initial product, JAZBI™ bone void filler family (JAZBI™ Filler), treats bony gaps created during trauma or surgeries. The properties of JAZBI™ can be adjusted to construct several bone implants. JAZBI™ cost-effective bone implants will be reimbursed using existing reimbursement codes with a market opportunity bigger than $2.5 B just for the initial product.